← All trials
NCT05329103
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2022
- Primary completion
- Apr 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Apr 14, 2022
- Last posted
- Oct 21, 2022
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peel Therapeutics IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.